Drug Trial Radar · NCT05109663
A Dose Escalation and Food Effect Study of SKLB1028 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Nov 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Apr 14, 2021
Primary completion
Jun 30, 2021
Study completion Jun 30, 2021
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study was to explore the safety, tolerability and pharmacokinetics (PK) of single ascending oral doses of SKLB1028 in healthy subjects. This study has also explored the effect of food on the PK of SKLB1028.
Conditions
- Healthy Subjects
Interventions
SKLB1028Drug
SKLB1028, capsule, oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events (TEAEs)Time frame: Throughout the study period, with an average of 10 days.
- Maximum plasma concentration (Cmax) of SKLB1028 in Part 2Time frame: Pre-dose and multiple timepoints up to 144 hours post-dose
- Area under the concentration-time curve from time 0 to last quantifiable concentration (AUC0-last) of SKLB1028 in Part 2Time frame: Pre-dose and multiple timepoints up to 144 hours post-dose
- Area under the concentration-time curve from time 0 to infinity (AUCinf) of SKLB1028 in Part 2Time frame: Pre-dose and multiple timepoints up to 144 hours post-dose
- Time to Cmax (Tmax) of SKLB1028 in Part 2Time frame: Pre-dose and multiple timepoints up to 144 hours post-dose
- Terminal-elimination half-life (T1/2) of SKLB1028 in Part 2Time frame: Pre-dose and multiple timepoints up to 144 hours post-dose
- Apparent volume of distribution (Vz/F) of SKLB1028 in Part 2Time frame: Pre-dose and multiple timepoints up to 144 hours post-dose
- Apparent clearance (CLz/F) of SKLB1028 in Part 2Time frame: Pre-dose and multiple timepoints up to 144 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Friendship Hospital, Capital Medical University
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.